RI S2866

Expands collaborative pharmacy practice agreements to allow pharmacists to partner with any healthcare "providers" rather than only physicians for drug therapy management of patients

Eliminates the six-member "collaborative practice committee" (previously composed of three pharmacy board appointees and three medical board appointees) that advised the director on collaborative practice regulation

Removes the approval/denial process requirement for collaborative practice agreements, allowing parties to begin acting under the agreement once all required documentation is complete

Expands the definition of "limited-function test" to include all CLIA-waived tests, removing the previous restriction to only blood glucose, hemoglobin A1c, cholesterol tests, and FDA-approved over-the-counter test kits

Effective date: July 1, 2026